Telemedical support
OtherParticipating sites will be advised by telemedicine support.
NCT Number: NCT03137589
Telemedicine allows providing expert know-ledge from specialized health centers to regional hospitals and practices. In this multicenter, prospective, non-interventional study hospitals and practices in NRW are supplied via a telematics platform with expertise from the university hospitals RWTH Aachen and Münster. The communication occurs via highly encrypted audio/video conference systems and a certified data exchange platform "Fallakte+". In total 40.000 outpatient and stationary patients with infectious diseases or need for intensive care should be treated with telemedical support. The participating hospitals and practices are randomly distributed into four clusters. The clusters are supplied with telemedicine at different time points but all clusters start at the same time collecting data from patient cohorts of infectiology and intensive care (e.g. symptom, therapeutic progress and outcome). The collected data is later compared to data obtained in the same way from patients treated with telemedical support and evaluated regarding differences in the quality of treatment, therapeutic process and the satisfaction of the patients with telemedicine. The aim is to improve the treatment quality in regional hospitals and practices of patients with serious and complex diseases and bring forward the application of telemedicine.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany
In future time the number of old people will significantly increase in Germany because of the demographic change taking place. The health care of the large number of old people will probably lead to a lack of physicians and an inefficient health care system. One strategy to tackle the problem could be telemedicine. Telemedicine makes it possible to provide know-ledge from experts to local hospitals and practices which otherwise need to send patients with serious and complex diseases to specialized trans-regional health centers. In this multicenter, prospective, non-interventional study hospitals and practices in NRW are supplied via a telematics platform with expert know-ledge from the university hospitals RWTH Aachen and Münster. The communication occurs via highly encrypted audio/video conference systems and a certified data exchange platform "Fallakte+".
In total 40.000 outpatient and stationary patients should be treated with telemedical support. Registered doctors will be involved in already existing practice networks to evaluate the potential for transfer and to ensure the sharing of know-ledge beyond the borders of individual sectors. The aim of the study is to improve the treatment quality of regional hospitals and practices and to increase the efficiency of the care of relevant patient cohort in the field of infectiology and intensive care with the main focus sepsis as those patient groups especially often require professional expertise for a successful therapy.
In the beginning of the study participating hospitals and practices are randomly distributed into four clusters (cluster randomization). The different clusters all start with the control phase but enter into the intervention phase at different times (stepped-wedge design). During the control phase data of patients with infection and intensive care patients routinely treated without the support of telemedicine are documented and the patients are asked to complete a questionnaire regarding health-related quality of life (SF36) directly after treatment and at two time points in the follow-up. The collected data will be later compared to data obtained in the same way from patients treated with telemedical support and evaluated regarding differences in the quality of treatment, therapeutic process and the satisfaction of the patients with telemedicine.
If the study shows that the treatment quality and therapeutic process of patients with infectious diseases or need for intensive care is improved by telemedicine, the telematics platform can be expanded and used by other specialized fields and users in future time.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participating sites will be advised by telemedicine support.
Time frame: through study completion, an average of 30 days up to a maximum of 1 year
The level of implementation of the 10 recommendations of the German Society of Infectious Diseases (Deutsche Gesellschaft für Infektiologie, DGI) within the framework of the Initiative "Decide wisely" ("Klug entscheiden").
Time frame: through study completion, an average of 30 days up to a maximum of 1 year
Rate of sepsis diagnosis
Time frame: through study completion, an average of 30 days up to a maximum of 1 year
Rate of ARDS Diagnosis
Time frame: through study completion, an average of 30 days up to a maximum of 1 year
Sepsis therapy in compliance with guidelines through for instance timely administration of antibiotics within 3 h and reduction of sepsis mortality.
Time frame: through study completion, an average of 30 days up to a maximum of 1 year
Measured against the evident ventilation targets, Ventilation with low ventilation volumes and low peak pressures: with controlled ventilation:
Breath volume of 6 ml/kg calculated Body ideal weight, PEEP setting in proportion with the necessary FiO2, plateau pressure < 30 cm H2O
Time frame: through study completion, an average of 30 days up to a maximum of 1 year
Measured by the Percentage of postoperatively continued perioperative Antibiotic prophylaxis
Time frame: At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
Rate of patients with dialysis requiring Kidney insufficiency in discharge from the Intensive care
Time frame: At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
Rate of transfer transport
Time frame: At discharge from Intensive Care Unit (through study completion; an average of 30 days up to a maximum of 1 year), through study completion, an average of 12 months and 24 months after discharge of ICU
Clinical studies 36-item Medical Outcomes Study Short-Form General Health Survey An instrument used to assess multidimensional health-related QOL, which measures 8 health related parameters: physical function, social function, physical role, emotional role, mental health, energy, pain, general health perceptions; each parameter is scored from 0 to 100 Managed care 36-Item Short-Form Functional and Perceived Health Status Survey A questionnaire which measures health status; the SF-36 also includes a list of 18 self-reported chronic conditions
Time frame: through study completion, an average of 30 days up to a maximum of 1 year
Defined as no filled out sepsis bundle despite presence of sepsis symptoms
Time frame: through study completion, an average of 30 days up to a maximum of 1 year
Sepsis mortality rate
Time frame: through study completion, an average of 30 days up to a maximum of 1 year
Hospital mortality rate
Time frame: At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
Length of stay in intensive care unit measured in hours
Time frame: At discharge from Hospital; after an average of 30 days up to a maximum of 1 year
Hospital stay measured in days
RWTH Aachen University
Other
Acronym: TELnet@NRW
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01264055
Bronchial Diseases, Bronchiectasis
Stanford, California, United States
View Trial DetailsNCT07673484
Allergic Contact Dermatitis, Cicatrix
Küçükçekmece, Istanbul, Turkey (Türkiye)
View Trial DetailsNCT00342589
Bacterial Infections and Mycoses, Infection
Bethesda, Maryland, United States
View Trial DetailsNCT07256405
Bone, Fracture
Marseille, Bouches-du-Rhône, France
View Trial Details